Spyre Therapeutics, Inc. (SYRE) insider trading.
In Q3 2026, insiders at Spyre Therapeutics, Inc. reported 39 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 32 sales worth $13.3M.
- Transactions
- 39
- Purchases (P)
- 0
- Sales (S)
- 32
- Net shares, P minus S
- -145,465
- Insiders
- 5
- Last filed
- 2026-09-03
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Burrows Scott L | Officer · Chief Financial Officer | 13 | 0 | 10 |
| Turtle Cameron | Director, Officer · Chief Executive Officer | 12 | 0 | 12 |
| King-Jones Heidy | Officer · See Remarks | 7 | 0 | 5 |
| Albers Jeffrey W. | Director | 4 | 0 | 3 |
| Sloan Sheldon | Officer · Chief Medical Officer | 3 | 0 | 2 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-02 | Burrows Scott L | S (D) | 18,232 | $89.35 | 79,762 | Form 4 |
| 2026-09-02 | King-Jones Heidy | S (D) | 400 | $90 | 2,845 | Form 4 |
| 2026-09-02 | King-Jones Heidy | M (A) | 400 | $14.5 | 3,245 | Form 4 |
| 2026-09-01 | Turtle Cameron | S (D) | 8,400 | $87.15 | 556,640 | Form 4 |
| 2026-09-01 | Turtle Cameron | S (D) | 2,500 | $86.36 | 565,040 | Form 4 |
| 2026-09-01 | Turtle Cameron | S (D) | 400 | $89.07 | 552,540 | Form 4 |
| 2026-09-01 | Turtle Cameron | S (D) | 3,700 | $88.06 | 552,940 | Form 4 |
| 2026-09-01 | Burrows Scott L | S (D) | 200 | $89.04 | 97,994 | Form 4 |
| 2026-09-01 | Burrows Scott L | S (D) | 2,016 | $88.03 | 98,194 | Form 4 |
| 2026-09-01 | Burrows Scott L | S (D) | 900 | $86.25 | 104,594 | Form 4 |
| 2026-09-01 | Burrows Scott L | S (D) | 4,384 | $87.11 | 100,210 | Form 4 |
| 2026-09-01 | Burrows Scott L | M (A) | 7,500 | $14.5 | 105,494 | Form 4 |
| 2026-09-01 | King-Jones Heidy | M (A) | 27,999 | $14.5 | 30,844 | Form 4 |
| 2026-09-01 | King-Jones Heidy | S (D) | 4,845 | $86.4 | 25,999 | Form 4 |
| 2026-09-01 | King-Jones Heidy | S (D) | 16,548 | $87.2 | 9,451 | Form 4 |
| 2026-09-01 | King-Jones Heidy | S (D) | 6,206 | $88.17 | 3,245 | Form 4 |
| 2026-09-01 | King-Jones Heidy | S (D) | 400 | $89.38 | 2,845 | Form 4 |
| 2026-08-07 | Albers Jeffrey W. | M (A) | 5,000 | $10.39 | 5,000 | Form 4 |
| 2026-08-07 | Albers Jeffrey W. | S (D) | 5,000 | $104.47 | 0 | Form 4 |
| 2026-08-07 | Albers Jeffrey W. | S (D) | 8,000 | $104.38 | 19,360 | Form 4 |
| 2026-08-07 | Albers Jeffrey W. | S (D) | 10,000 | $104.68 | 9,360 | Form 4 |
| 2026-08-03 | Turtle Cameron | S (D) | 800 | $93.97 | 581,740 | Form 4 |
| 2026-08-03 | Turtle Cameron | S (D) | 7,157 | $95.1 | 574,583 | Form 4 |
| 2026-08-03 | Turtle Cameron | S (D) | 5,635 | $95.93 | 568,948 | Form 4 |
| 2026-08-03 | Turtle Cameron | S (D) | 1,392 | $96.82 | 567,556 | Form 4 |
| 2026-08-03 | Turtle Cameron | S (D) | 16 | $97.46 | 567,540 | Form 4 |
| 2026-08-03 | Burrows Scott L | S (D) | 2,300 | $96.3 | 98,094 | Form 4 |
| 2026-08-03 | Burrows Scott L | S (D) | 5,100 | $95.21 | 100,394 | Form 4 |
| 2026-08-03 | Burrows Scott L | M (A) | 7,500 | $14.5 | 105,494 | Form 4 |
| 2026-08-03 | Burrows Scott L | S (D) | 100 | $97.1 | 97,994 | Form 4 |
| 2026-07-01 | Turtle Cameron | S (D) | 4,234 | $88.12 | 583,130 | Form 4 |
| 2026-07-01 | Turtle Cameron | S (D) | 590 | $88.91 | 582,540 | Form 4 |
| 2026-07-01 | Turtle Cameron | S (D) | 10,176 | $87.44 | 587,364 | Form 4 |
| 2026-07-01 | Sloan Sheldon | S (D) | 1,834 | $88.34 | 0 | Form 4 |
| 2026-07-01 | Sloan Sheldon | S (D) | 6,500 | $87.52 | 1,834 | Form 4 |
| 2026-07-01 | Sloan Sheldon | M (A) | 8,334 | $27.46 | 8,334 | Form 4 |
| 2026-07-01 | Burrows Scott L | S (D) | 5,775 | $87.55 | 99,719 | Form 4 |
| 2026-07-01 | Burrows Scott L | S (D) | 1,725 | $88.37 | 97,994 | Form 4 |
| 2026-07-01 | Burrows Scott L | M (A) | 7,500 | $14.5 | 105,494 | Form 4 |
Transaction codes in this quarter
Get SYRE insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1636282&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · SYRE company page · Spyre Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Spyre Therapeutics, Inc. (SYRE)?
In Q3 2026, insiders at Spyre Therapeutics, Inc. reported 39 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 32 sales worth $13.3M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Spyre Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/syre.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.